Drugs that contain Omadacycline Tosylate
1. List of Nuzyra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7553828 | PARATEK PHARMS INC | 9-aminomethyl substituted minocycline compounds |
Jun, 2023
(a month from now) | |
| US7326696 | PARATEK PHARMS INC | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(5 months from now) | |
| US8383610 | PARATEK PHARMS INC | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10124014 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(5 years from now) | |
| US9724358 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(5 years from now) | |
| US9265740 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(5 years from now) | |
| US9314475 | PARATEK PHARMS INC | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(7 years from now) | |
| US10111890 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(14 years from now) | |
| US10835542 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(14 years from now) | |
| US10383884 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 2, 2023 |
| Generating Antibiotic Incentives Now (GAIN) | Oct 2, 2028 |
NCE-1 date: 2027-10-03
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections; Treatment of subjects having bacterial skin or skin structure infection; Treatment ...
Dosage: POWDER;INTRAVENOUS
NUZYRA family patents
54
United States
22
Japan
17
European Union
14
China
13
Australia
10
Korea, Republic of
9
Taiwan, Province of China
9
Canada
7
Brazil
6
Denmark
6
Mexico
6
Croatia
6
Spain
6
EA
5
Russia
5
Slovenia
5
Portugal
4
South Africa
4
Hungary
4
Singapore
4
Poland
3
Hong Kong
3
Lithuania
3
Cyprus
3
New Zealand
2
Israel
2
Austria
2
Morocco
2
Philippines
2
Colombia
2
Argentina
2
Czech Republic
2
Chile
2
Ecuador
2
Tunisia
1
Turkey
1
Norway
1
Germany
1
Malaysia
1
Ukraine
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic